On Monday, Zymeworks BC Inc (NASDAQ: ZYME) opened higher 3.48% from the last session, before settling in for the closing price of $10.63. Price fluctuations for ZYME have ranged from $7.97 to $17.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 273.04% over the last five years. Company’s average yearly earnings per share was noted -3.28% at the time writing. With a float of $67.30 million, this company’s outstanding shares have now reached $68.96 million.
The firm has a total of 286 workers. Let’s measure their productivity. In terms of profitability, gross margin is 50.29%, operating margin of -157.03%, and the pretax margin is -152.82%.
Zymeworks BC Inc (ZYME) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zymeworks BC Inc is 4.07%, while institutional ownership is 98.07%. The most recent insider transaction that took place on Apr 04 ’25, was worth 2,193,800. In this transaction Director of this company bought 196,438 shares at a rate of $11.17, taking the stock ownership to the 17,699,774 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Director bought 120,770 for $11.84, making the entire transaction worth $1,430,170. This insider now owns 17,503,336 shares in total.
Zymeworks BC Inc (ZYME) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.14% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Check out the current performance indicators for Zymeworks BC Inc (ZYME). In the past quarter, the stock posted a quick ratio of 3.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Analysing the last 5-days average volume posted by the [Zymeworks BC Inc, ZYME], we can find that recorded value of 1.3 million was better than the volume posted last year of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 43.54%. Additionally, its Average True Range was 0.82.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 24.50%, which indicates a significant decrease from 52.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.93% in the past 14 days, which was higher than the 57.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.78, while its 200-day Moving Average is $12.67. Now, the first resistance to watch is $11.20. This is followed by the second major resistance level at $11.41. The third major resistance level sits at $11.63. If the price goes on to break the first support level at $10.77, it is likely to go to the next support level at $10.55. Now, if the price goes above the second support level, the third support stands at $10.34.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
There are currently 69,577K shares outstanding in the company with a market cap of 771.65 million. Presently, the company’s annual sales total 76,300 K according to its annual income of -122,700 K. Last quarter, the company’s sales amounted to 31,030 K and its income totaled -23,510 K.
